2-methylsulfanyl-6-phenyl-7-[4-[[4-(3-pyridin-4-yl-1H-pyrazol-5-yl)piperidin-1-yl]methyl]phenyl]pyrido[2,3-d]pyrimidine | 882047-23-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-methylsulfanyl-6-phenyl-7-[4-[[4-(3-pyridin-4-yl-1H-pyrazol-5-yl)piperidin-1-yl]methyl]phenyl]pyrido[2,3-d]pyrimidine
• CAS: 882047-23-6
• 化学式: C₃₄H₃₁N₇S
• 分子量: 569.733
• InChiKey: HEJHZECVCFFTIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  42
• 可旋转键数：
  7
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-[2-(methylthio)-6-phenylpyrido[2,3-d]pyrimidin-7-yl]benzaldehyde 、 4-(3-(piperidin-4-yl)-1H-pyrazol-5-yl)pyridine 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 2-methylsulfanyl-6-phenyl-7-[4-[[4-(3-pyridin-4-yl-1H-pyrazol-5-yl)piperidin-1-yl]methyl]phenyl]pyrido[2,3-d]pyrimidine
  参考文献：
  名称：

  Development of Pyridopyrimidines as Potent Akt1/2 Inhibitors

  摘要：

  This communication reports a new synthetic route of pyridopyrimidines to facilitate their structural optimization in a library fashion and describes the development of pyridopyrimidines that have excellent enzymatic and cell potency against Akt1 and Akt2. This series also shows a high level of selectivity over other closely related kinases and significantly improved caspase-3 activity with the more optimized compounds. (c) 2008 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2008.01.054

文献信息

• Inhibitors of Akt Activity
  申请人：Bilodeau T. Mark

  公开号：US20070254901A1

  公开（公告）日：2007-11-01

  The present invention is directed to compounds which contain substituted 5-deazapteridine moieties which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.

  本发明涉及含有取代的5-脱氨嘌呤基团的化合物，该化合物抑制Akt蛋白激酶的活性。该发明还涉及含有本发明化合物的化疗组合物以及治疗癌症的方法，包括给予本发明化合物的治疗方法。
• INHIBITORS OF AKT ACTIVITY
  申请人：Merck & Co., Inc.

  公开号：EP1784175A2

  公开（公告）日：2007-05-16
• EP1784175A4
  申请人：——

  公开号：EP1784175A4

  公开（公告）日：2009-07-22
• USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES
  申请人：DelMar Pharmaceuticals, Inc.

  公开号：US20180071244A1

  公开（公告）日：2018-03-15

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N 7 methylation and that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents (e.g. cisplatin) and can possess additive or super-additive effects.
• US7544677B2
  申请人：——

  公开号：US7544677B2

  公开（公告）日：2009-06-09